Legitimate question... Since at least mid-2017, there have been nonpublic preclinical trials and/or discussions going on with Pestell and Prostagene at a minimum. Do you think that Pourhassan, or any other member of the board or management, could actually buy on the open market while actively in possession of material nonpublic information, or even in active M&A discussions? I’m no securities lawyer and I certainly don’t know the answer, but I imagine the prohibitions would be strict.
Market Data 
Markets 
AI
